<DOC>
	<DOCNO>NCT00520052</DOCNO>
	<brief_summary>The aim study determine 3 monthly infusion zoledronic acid , give one year , improve bone mineral density osteoporotic patient undergo androgen deprivation therapy prostate cancer</brief_summary>
	<brief_title>Frequency Zoledronic Acid Prevent Further Bone Loss Osteoporotic Patients Requiring Androgen Deprivation Therapy Prostate Cancer</brief_title>
	<detailed_description>Androgen Deprivation Therapy mainstay treatment advanced prostate cancer . However associate accelerated bone loss , osteoporosis fracture . Previous study look use zoledronic acid predominantly study men normal osteopenic bone mineral density . However , show upto 40 % men present prostate cancer osteoporosis risk osteoporotic fracture . Our aim evaluate efficiency zoledronic acid 2 group osteoporotic patient , undergo treatment LHRH agonists antiandrogens.Peripheral axial bone densitometry use measure percentage change bone mineral density 3 year . The first year patient LHRH antiandrogen , second year continue androgen deprivation therapy zoledronic acid . Then bone mineral density measure one year follow last infusion zoledronic acid ascertain optimum frequency administration . The study also involve monitor serum urine bone turnover marker .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>patient locally advanced prostate cancer progress normal/ osteopenic bone mineral density osteoporosis LHRH agonist ( LHRH Group ) . Also patient commence Bicalutamide due osteoporosis presentation ( Bicalutamide Group ) patient elevate prostate specific antigen , illness medication would affect bone mineral metabolism , previous bisphosphonate treatment , severe hepatic renal insufficiency .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>bisphosphonates , prostate cancer , bone density , osteoporosis</keyword>
</DOC>